Screening for Factor V Leiden Mutation (FVL)in Users of Combined Oral Contraceptives (COC)or Hormone Replacement Therapy (HRT)


Authors: D. Cibula 1;  V. Unzeitig 2;  J. Živný 1
Authors‘ workplace: Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, přednosta prof. MUDr. J. Živný, DrSc. 2Gynekologicko-porodnická klinika, LF MU a FN Brno, přednosta prof. MUDr. P. Ventruba, DrSc. 1
Published in: Čes. Gynek.2003, , č. 3 s. 167-174
Category:

Overview

Objective:
Analysis of the issue of screening for Factor V Leiden mutation (FVL) in users of combinedoral contraceptives (COC) or hormone replacement therapy (HRT).Design: Review article.Setting: Department of Obstetrics and Gynecology, Charles University and GeneralFaculty Hospital,Prague.Methods: Review of published facts, analysis of possibilities to screen all users or to test risk groupsin the current situation in the Czech Republic.Conclusion: 1) Screening for FVL in allCOCorHRTusers is not recommended mostly for economicalreasons. 2) Testing for FVL is indicated in women with a positive family history of thromboembolicdisease and in obese women, if they consider COC or HRT despite our recommendation or in casethere is a medical indication. 3) Deep venous thrombosis or pulmonary embolism are absolutecontraindications of COC or HRT regardless of the presence of FVL.

Key words:
combined oral contraceptives, hormone replacement therapy, thromboembolic disease,Factor V Leiden mutation, hereditary thrombophilias

Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP.

Labels
Paediatric gynaecology Gynaecology and obstetrics Reproduction medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

×